Investment case
Charles River Laboratories International, Inc.
CRL · 3 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 3 macro, policy, and market developments to Charles River Laboratories International, Inc. since 2026-09-03. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CRL yet, so no modelled value is shown. The CRL valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CRL on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
Increased competition in the early-phase clinical research organization (CRO) market, potentially impacting pricing power or market share for established players.
· Moves market share in early phase cro services, pricing power in competitive segments
What changed, by assumption
- 2026-09-03Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
- 2026-09-03Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-05 | Share count | Bearish | Repurchase reduces shares outstanding. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | Fortrea Acquires Worldwide Clinical Trials Early Phase Unit for $45M | watch | 3-12m | 0.30 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M | watch | 3-12m | 0.20 |
| 2026-09-03 | Fortrea to Acquire Worldwide Clinical Trials Early Phase Unit for $45M | mixed | 3-12m | 0.20 |